Hanall Biopharma Co., Ltd. (009420) Financial Statements

― Followers

Hanall Biopharma Co., Ltd. Financial Overview

Hanall Biopharma Co., Ltd.'s market cap is currently ₩2.47T. The company's EPS TTM is ₩-482.08; its P/E ratio is -99.05; Hanall Biopharma Co., Ltd. is scheduled to report earnings on July 29, 2026, and the estimated EPS forecast is ₩―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	₩ 155.18B	₩ 138.94B	₩ 134.91B	₩ 110.00B	₩ 101.59B
Gross Profit	₩ 79.10B	₩ 73.31B	₩ 75.04B	₩ 61.97B	₩ 60.33B
Operating Income	₩ -1.61B	₩ 230.47M	₩ 3.06B	₩ 1.51B	₩ 10.10B
EBITDA	₩ 1.94B	₩ 3.35B	₩ 6.58B	₩ 5.05B	₩ 11.45B
Net Income	₩ -5.56B	₩ -1.80B	₩ 3.51B	₩ 251.47M	₩ 8.90B
Balance Sheet
Cash & Short-Term Investments	₩ 24.74B	₩ 24.71B	₩ 56.50B	₩ 53.93B	₩ 80.57B
Total Assets	₩ 225.22B	₩ 212.88B	₩ 239.75B	₩ 213.45B	₩ 198.48B
Total Debt	₩ 31.92B	₩ 1.45B	₩ 1.29B	₩ 1.31B	₩ 1.34B
Net Debt	₩ 7.17B	₩ -14.94B	₩ -32.43B	₩ -15.53B	₩ -11.46B
Total Liabilities	₩ 63.54B	₩ 44.53B	₩ 53.53B	₩ 45.19B	₩ 34.99B
Stockholders' Equity	₩ 161.68B	₩ 168.35B	₩ 186.22B	₩ 168.26B	₩ 163.49B
Cash Flow
Free Cash Flow	₩ -3.29B	₩ -13.71B	₩ 20.45B	₩ 17.53B	₩ -8.16B
Operating Cash Flow	₩ -2.34B	₩ 9.36B	₩ 29.64B	₩ 25.20B	₩ 839.87M
Investing Cash Flow	₩ -18.83B	₩ -27.49B	₩ -11.89B	₩ -10.59B	₩ 8.03B
Financing Cash Flow	₩ 29.57B	₩ 759.59M	₩ -813.51M	₩ -10.64B	₩ -306.53M

Currency in KRW

Hanall Biopharma Co., Ltd. Earnings and Revenue History

Income Statement >

Hanall Biopharma Co., Ltd. Debt to Assets

Balance Sheet >

Hanall Biopharma Co., Ltd. Cash Flow

Cash Flow >

Hanall Biopharma Co., Ltd. Forecast EPS vs Actual EPS

Earnings >